A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics
Summary The influence of an antacid on droxicam pharmacokinetics was investigated in 12 healthy male volunteers. A two way cross-over study was performed after the oral administration of 20 mg of droxicam (Ombolan capsules) and droxicam together with an antacid (Mucal powder). The plasma concentrations of piroxicam, the active moiety of droxicam, were determined by a high-performance liquid chromatographic method. The pharmacokinetic parameter values (mean ± RSD) of piroxicam after administration of droxicam alone were: $ AUC_{0→∞} $=125.5 ± 25.1 μg.h/l. $ C_{max} $=2.08 ± 19.9 μg/l, $ t_{max} $=7.08±36.8 h and $ t_{1/2} $=46.3 ± 27.0 h. Following administration of droxicam together with the antacid the values obtained for the same parameters were: $ AUC_{0→∞} $=135.1 ± 24.1 μg.h/l, $ C_{max} $=1.85 ± 23.9 μg/l, $ t_{max} $=8.17 ± 34.9 h and $ t_{1/2} $=52.0 ± 22.4 h. These results indicate that concurrent administration of the antacid does not significantly change the bioavailability and pharmacokinetics of droxicam..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1995 |
|---|---|
| Erschienen: |
1995 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
European journal of drug metabolism and pharmacokinetics - 20(1995), 4 vom: Dez., Seite 275-279 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maya, M. T. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| Anmerkungen: |
© Springer-Verlag 1995 |
|---|
| doi: |
10.1007/BF03190244 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2028710039 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2028710039 | ||
| 003 | DE-627 | ||
| 005 | 20230516090015.0 | ||
| 007 | tu | ||
| 008 | 200819s1995 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/BF03190244 |2 doi | |
| 035 | |a (DE-627)OLC2028710039 | ||
| 035 | |a (DE-He213)BF03190244-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Maya, M. T. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics |
| 264 | 1 | |c 1995 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Springer-Verlag 1995 | ||
| 520 | |a Summary The influence of an antacid on droxicam pharmacokinetics was investigated in 12 healthy male volunteers. A two way cross-over study was performed after the oral administration of 20 mg of droxicam (Ombolan capsules) and droxicam together with an antacid (Mucal powder). The plasma concentrations of piroxicam, the active moiety of droxicam, were determined by a high-performance liquid chromatographic method. The pharmacokinetic parameter values (mean ± RSD) of piroxicam after administration of droxicam alone were: $ AUC_{0→∞} $=125.5 ± 25.1 μg.h/l. $ C_{max} $=2.08 ± 19.9 μg/l, $ t_{max} $=7.08±36.8 h and $ t_{1/2} $=46.3 ± 27.0 h. Following administration of droxicam together with the antacid the values obtained for the same parameters were: $ AUC_{0→∞} $=135.1 ± 24.1 μg.h/l, $ C_{max} $=1.85 ± 23.9 μg/l, $ t_{max} $=8.17 ± 34.9 h and $ t_{1/2} $=52.0 ± 22.4 h. These results indicate that concurrent administration of the antacid does not significantly change the bioavailability and pharmacokinetics of droxicam. | ||
| 650 | 4 | |a Droxicam | |
| 650 | 4 | |a human pharmacokinetics | |
| 650 | 4 | |a bioavailability | |
| 700 | 1 | |a Pais, J. P. |4 aut | |
| 700 | 1 | |a Da Silva, J. Ruas |4 aut | |
| 700 | 1 | |a Morais, J. A. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of drug metabolism and pharmacokinetics |d Springer-Verlag, 1976 |g 20(1995), 4 vom: Dez., Seite 275-279 |w (DE-627)129447986 |w (DE-600)196729-0 |w (DE-576)435518917 |x 0398-7639 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:1995 |g number:4 |g month:12 |g pages:275-279 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/BF03190244 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_21 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4305 | ||
| 936 | b | k | |a 44.40 |q VZ |
| 951 | |a AR | ||
| 952 | |d 20 |j 1995 |e 4 |c 12 |h 275-279 | ||